Actinogen Medical LimitedASX: ACW

ACW receives further $1.9m FY2025 R&D rebate from ATO

· Issued by Actinogen Medical Limited

Filed with ASX · · 3 pages · English

Summary by 6ix AI

Actinogen Medical Limited has announced the receipt of a research and development tax incentive rebate from the Australian Tax Office related to the financial year. The rebate amounts to a significant sum and is part of the company's funding strategy as it progresses in its Alzheimer's clinical trial. This announcement highlights the importance of the RDTI program for the company's ongoing operations and future milestones.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Actinogen Medical Limited on 6ix

Earlier from Actinogen Medical

Later from Actinogen Medical

All Actinogen Medical news releases